Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.
|Number of pages||3|
|Publication status||Published - Oct 2020|
- Cyproterone acetate/ethinylestradiol
- Real world data
- Risk minimization